Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Chiome Bioscience stock price, quote, forecast and news

4583.T
JP3205350006

Price

122.00
Today +/-
+0
Today %
+0 %
P

Chiome Bioscience Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Chiome Bioscience, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Chiome Bioscience from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Chiome Bioscience’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Chiome Bioscience. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Chiome Bioscience’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Chiome Bioscience’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Chiome Bioscience’s growth potential.

Chiome Bioscience Revenue, EBIT and net profit per share

DateChiome Bioscience RevenueChiome Bioscience EBITChiome Bioscience Net Income
2023682.46 M undefined-1.21 B undefined-1.22 B undefined
2022630.82 M undefined-1.26 B undefined-1.24 B undefined
2021712.93 M undefined-1.33 B undefined-1.48 B undefined
2020480.85 M undefined-1.28 B undefined-1.29 B undefined
2019447.58 M undefined-1.4 B undefined-1.4 B undefined
2018212.85 M undefined-1.54 B undefined-1.53 B undefined
2017259.9 M undefined-887.87 M undefined-882.57 M undefined
2016252.22 M undefined-1.04 B undefined-1.49 B undefined
2015280.11 M undefined-1.27 B undefined-1.28 B undefined
2014277.8 M undefined-865.6 M undefined-863.3 M undefined
2013435 M undefined-708.9 M undefined-757.6 M undefined
2012324.1 M undefined-413.2 M undefined-426.9 M undefined
2011633.2 M undefined-7.3 M undefined-44.4 M undefined
2010463.2 M undefined-231.2 M undefined-180.2 M undefined
2009380.8 M undefined-201.5 M undefined-164.4 M undefined
2008161.8 M undefined-213 M undefined-204.6 M undefined
200734.2 M undefined-248.9 M undefined-227.3 M undefined
200613.9 M undefined-193.8 M undefined-141.9 M undefined

Chiome Bioscience Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200620072008200920102011201220132014201520162017201820192020202120222023
1334161380463633324435277280252259212447480712630682
-161.54373.53136.0221.8436.72-48.8234.26-36.321.08-10.002.78-18.15110.857.3848.33-11.528.25
30.7735.2942.2457.3757.0266.1962.9660.0067.8750.7145.2467.1852.3663.5351.0459.2755.2458.36
41268218264419204261188142114174111284245422348398
-193-248-213-201-231-7-413-708-865-1,269-1,042-887-1,539-1,401-1,283-1,334-1,258-1,205
-1,484.62-729.41-132.30-52.89-49.89-1.11-127.47-162.76-312.27-453.21-413.49-342.47-725.94-313.42-267.29-187.36-199.68-176.69
-141-227-204-164-180-44-426-757-863-1,282-1,491-882-1,533-1,403-1,293-1,479-1,242-1,220
-60.99-10.13-19.619.76-75.56868.1877.7014.0048.5516.30-40.8573.81-8.48-7.8414.39-16.02-1.77
16.416.416.416.416.414.716.819.120.42222.6326.3626.7831.4735.8840.2843.9849.55
------------------
Details

Keystats

ⓘ

Revenue and Growth

The Chiome Bioscience Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Chiome Bioscience is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Chiome Bioscience provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Chiome Bioscience's financial health and stability.

Assets

Chiome Bioscience's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Chiome Bioscience must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Chiome Bioscience after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Chiome Bioscience's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200920102011201220132014201520162017201820192020202120222023
-162-177-42-424-743-885-1,280-1,501-880-1,531-1,401-1,290-1,466-1,237-1,215
43755655738010211310743211
000000000000000
164-38-95-8120-3-10-172-164-140-7318245144
-40-54324-21827435000014900
341210000000112
111113032222-435
4-195-48-373-552-789-1,162-969-867-1,688-1,537-1,360-1,131-1,191-1,069
-206-135-3-42-279-118-168-10-4000000
-0.26-0.09-0-0.11-0.19-0.62-1.781.99-0.140-0.03-0-0.0400
-0.060.050-0.070.09-0.5-1.612-0.130-0.03-0-0.0400
000000000000000
195-65-4547-111-20100-45-50-4018031107
0.070.450.50.374.22.150.021.460.5301.351.770.251.130.55
0.270.380.420.464.12.130.121.430.48-0.011.341.940.271.130.67
00-30491403180-6-4-51405
000000000000000
0.010.10.37-0.023.360.73-2.822.45-0.53-1.7-0.220.58-0.9-0.06-0.4
-202.78-330.86-52.63-416.06-831.68-908.28-1,330.09-980.86-872.18-1,688.71-1,537.36-1,360.14-1,131.29-1,191.01-1,069.19
000000000000000

Chiome Bioscience stock margins

The Chiome Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Chiome Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Chiome Bioscience.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Chiome Bioscience's sales revenue. A higher gross margin percentage indicates that the Chiome Bioscience retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Chiome Bioscience's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Chiome Bioscience's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Chiome Bioscience's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Chiome Bioscience. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Chiome Bioscience's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Chiome Bioscience Margin History

Chiome Bioscience Gross marginChiome Bioscience Profit marginChiome Bioscience EBIT marginChiome Bioscience Profit margin
202358.41 %-176.59 %-178.77 %
202255.3 %-199.53 %-197.03 %
202159.26 %-187.16 %-207.58 %
202051.01 %-266.95 %-269.06 %
201963.6 %-313.23 %-313.65 %
201852.28 %-723.1 %-720.46 %
201767.11 %-341.63 %-339.59 %
201645.36 %-413.28 %-591.23 %
201550.71 %-453.36 %-457.93 %
201467.93 %-311.59 %-310.76 %
201360 %-162.97 %-174.16 %
201263.16 %-127.49 %-131.72 %
201166.3 %-1.15 %-7.01 %
201057.08 %-49.91 %-38.9 %
200957.43 %-52.91 %-43.17 %
200842.09 %-131.64 %-126.45 %
200736.84 %-727.78 %-664.62 %
200633.81 %-1,394.24 %-1,020.86 %

Chiome Bioscience Stock Sales Revenue, EBIT, Earnings per Share

The Chiome Bioscience earnings per share therefore indicates how much revenue Chiome Bioscience has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Chiome Bioscience earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Chiome Bioscience's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Chiome Bioscience’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Chiome Bioscience's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Chiome Bioscience Revenue, EBIT and net profit per share

DateChiome Bioscience Sales per ShareChiome Bioscience EBIT per shareChiome Bioscience Earnings per Share
202313.77 undefined-24.32 undefined-24.62 undefined
202214.34 undefined-28.62 undefined-28.26 undefined
202117.7 undefined-33.13 undefined-36.74 undefined
202013.4 undefined-35.78 undefined-36.06 undefined
201914.22 undefined-44.55 undefined-44.61 undefined
20187.95 undefined-57.47 undefined-57.26 undefined
20179.86 undefined-33.68 undefined-33.48 undefined
201611.15 undefined-46.07 undefined-65.91 undefined
201512.73 undefined-57.71 undefined-58.29 undefined
201413.62 undefined-42.43 undefined-42.32 undefined
201322.77 undefined-37.12 undefined-39.66 undefined
201219.29 undefined-24.6 undefined-25.41 undefined
201143.07 undefined-0.5 undefined-3.02 undefined
201028.24 undefined-14.1 undefined-10.99 undefined
200923.22 undefined-12.29 undefined-10.02 undefined
20089.87 undefined-12.99 undefined-12.48 undefined
20072.09 undefined-15.18 undefined-13.86 undefined
20060.85 undefined-11.82 undefined-8.65 undefined

Chiome Bioscience business model

Chiome Bioscience is one of the most popular companies on Eulerpool.com.

Chiome Bioscience historical P/E ratio, EBIT, and P/S ratio.

Chiome Bioscience shares outstanding

The number of shares was Chiome Bioscience in 2023 — This indicates how many shares 49.545 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Chiome Bioscience earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Chiome Bioscience's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Chiome Bioscience’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Chiome Bioscience's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Chiome Bioscience Stock splits

In Chiome Bioscience's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Chiome Bioscience.

Chiome Bioscience list of shareholders

%
Name
Stocks
Change
Date
2.53 % SBI Securities Co., Ltd.1,428,550-642,66012/31/2023
1.77 % Watanabe (Kenji)1,000,000350,00012/31/2023
1.77 % Ueda Yagi Tanshi Co., Ltd.998,800998,80012/31/2023
1.71 % Ota (Kunihiro)962,700012/31/2023
1.67 % Growth Capital KK940,00060,0001/19/2024
1.06 % Yoshimura (Koji)600,000012/31/2023
0.88 % Iisaku (Tetsuo)497,000012/31/2023
0.81 % Hirata (Shigekazu)455,00015,40012/31/2023
0.71 % Yamato (Fukutaro)400,000012/31/2023
0.61 % SMBC Nikko Securities Inc.346,600-35,70011/30/2022
1
2

Chiome Bioscience Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Chugai Pharmaceutical Stock
Chugai Pharmaceutical
SupplierCustomer0,710,910,780,220,690,54
Ono Pharmaceutical Stock
Ono Pharmaceutical
SupplierCustomer0,54-0,44-0,11-0,34-0,70-0,07
Shanghai Henlius Biotech Stock
Shanghai Henlius Biotech
SupplierCustomer0,470,780,510,640,770,66
Kyowa Kirin Stock
Kyowa Kirin
SupplierCustomer0,44-0,090,370,680,860,16
ADC Therapeutics Stock
ADC Therapeutics
SupplierCustomer-0,050,770,480,620,780,73
H.U.Group Holdings Stock
H.U.Group Holdings
SupplierCustomer-0,300,490,54-0,050,10-0,30
1

Most common questions regarding Chiome Bioscience

What is the P/E ratio of Chiome Bioscience 2024?

The P/E ratio cannot be calculated for Chiome Bioscience at the moment.

What is the P/S ratio of Chiome Bioscience 2024?

The P/S cannot be calculated for Chiome Bioscience currently.

What is the AlleAktien quality score of Chiome Bioscience?

The AlleAktien quality score for Chiome Bioscience is 4/10.

What is the revenue of Chiome Bioscience 2024?

The revenue cannot currently be calculated for Chiome Bioscience.

How high is the profit of Chiome Bioscience 2024?

The profit cannot currently be calculated for Chiome Bioscience.

What is the business model of Chiome Bioscience

No history available for Chiome Bioscience.

What is the Chiome Bioscience dividend?

Chiome Bioscience pays a dividend of 0 JPY distributed over payouts per year.

How often does Chiome Bioscience pay dividends?

The dividend cannot currently be calculated for Chiome Bioscience or the company does not pay out a dividend.

What is the Chiome Bioscience ISIN?

The ISIN of Chiome Bioscience is JP3205350006.

What is the Chiome Bioscience ticker?

The ticker of Chiome Bioscience is 4583.T.

How much dividend does Chiome Bioscience pay?

Over the past 12 months, Chiome Bioscience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Chiome Bioscience is expected to pay a dividend of 0 JPY.

What is the dividend yield of Chiome Bioscience?

The current dividend yield of Chiome Bioscience is .

When does Chiome Bioscience pay dividends?

Chiome Bioscience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Chiome Bioscience?

Chiome Bioscience paid dividends every year for the past 0 years.

What is the dividend of Chiome Bioscience?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Chiome Bioscience located?

Chiome Bioscience is assigned to the 'Health' sector.

Wann musste ich die Aktien von Chiome Bioscience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Chiome Bioscience from 7/17/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 7/17/2024.

When did Chiome Bioscience pay the last dividend?

The last dividend was paid out on 7/17/2024.

What was the dividend of Chiome Bioscience in the year 2023?

In the year 2023, Chiome Bioscience distributed 0 JPY as dividends.

In which currency does Chiome Bioscience pay out the dividend?

The dividends of Chiome Bioscience are distributed in JPY.

All fundamentals about Chiome Bioscience

Our stock analysis for Chiome Bioscience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chiome Bioscience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.